



## National Coverage Determination (NCD) Update

**Benefit:** Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

**Effective Date:** April 7, 2022

The Centers for Medicare and Medicaid Services (CMS) notified on April 7, 2022 of its determination to cover the Food and Drug Administration (FDA) approved monoclonal antibodies against amyloid for the treatment of Alzheimer's disease. Amyloid protein is essential for the proper functioning of the brain, and if it is eliminated from the brain, it could cause problems in the ability to learn and memorize, as well as a greater and faster accumulation of plaques in Alzheimer's disease.

This approval will be under the criteria outlined under Coverage Evidence Development (CED) for patients who have a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia.

Access the memo containing the CMS decision at: <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305&fromTracking=Y&>

MCS Classicare is an HMO plan subscribed by MCS Advantage, Inc. MCS Advantage, Inc. cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo. MCS Advantage, Inc. complies with federal civil rights laws applicable and does not discriminate on grounds of race, color, national origin, age, disability or sex. MCS Advantage, Inc. ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1.866.627.8183 (TTY: 1.866.627.8182). ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.627.8183 (TTY: 1.866.627.8182). 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.866.627.8183 (TTY: 1.866.627.8182)。1.866.627.8183 (TTY: 1.866.627.8182)。注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電